Tocilizumab (TCZ), a recombinant humanized monoclonal antibody, used for severe rheumatoid arthritis and life-threatening cytochrome release syndrome, may be a potential treatment option for COVID-19 infection. Patients with severe COVID-19 infection showed an increase in pro-inflammatory cytokines; hence, it was thought that blocking the receptor of these agents may reduce the inflammatory response to COVID-19. CADTH has conducted a report to review the evidence on the clinical effectiveness of TCZ for the treatment and prevention of COVID-19.
Link to Report
Was this site helpful?
If you couldn’t find what you are looking for, please submit a request.